Heart stent showdown: one branch or two?

NCT ID NCT00376571

Completed Disease control Sponsor: Aarhus University Hospital Skejby Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the best way to use drug-eluting stents (tiny mesh tubes that release medication) in patients with coronary artery disease where the blockage is at a fork (bifurcation). 413 patients were randomly assigned to get stents in both branches of the fork or only in the main branch, with optional treatment of the side branch. The goal was to see which approach reduces the risk of heart-related death, heart attack, stent clotting, or the need for repeat procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: drug-eluting stent
What this could lead to: If successful, this could help doctors choose the safest and most effective stenting strategy for patients with blocked arteries at a fork (bifurcation).
What could go wrong: This is a completed Phase 4 trial with 413 patients, so results are already known. The findings may not apply to all types of blockages or newer stents.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

Contacts and locations

Locations

Skejby Hospital, University of Aarhus

Aarhus, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.